UGISense Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series B
- Investors
-
2
UGISense General Information
Description
Developer of a biotechnology platform designed to develop antisense drugs for genetic and acquired conditions. The company offers a platform featuring highly stable, specific, and effective Ugimers molecules with customizable chemical modifications, enabling pharmaceutical partners to develop and improve therapies for diseases.
Contact Information
Website
www.ugisense.comCorporate Office
- Otto-Hahn-Straße 15
- 44227 Dortmund
- Germany
Corporate Office
- Otto-Hahn-Straße 15
- 44227 Dortmund
- Germany
UGISense Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 29-Apr-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 24-May-2018 | Completed | Generating Revenue | |||
| 1. Corporate | 12-Oct-2016 | $1.34M | $1.34M | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
UGISense Patents
UGISense Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-2683186-T3 | Monomers and oligomers of peptidonucleic acid | Active | 16-May-2014 | ||
| AU-2015258476-A1 | Peptide nucleic acid monomers and oligomers | Active | 16-May-2014 | ||
| AU-2015258476-B2 | Peptide nucleic acid monomers and oligomers | Active | 16-May-2014 | ||
| CA-2949185-A1 | Peptide nucleic acid monomers and oligomers | Active | 16-May-2014 | ||
| CA-2949185-C | Peptide nucleic acid monomers and oligomers | Active | 16-May-2014 | C07D473/18 |
UGISense Signals
UGISense Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Sparkasse Dortmund | Venture Capital | Minority | ||
| Lead Discovery Center | Corporation | Minority |
UGISense FAQs
-
When was UGISense founded?
UGISense was founded in 2016.
-
Where is UGISense headquartered?
UGISense is headquartered in Dortmund, Germany.
-
What is the size of UGISense?
UGISense has 6 total employees.
-
What industry is UGISense in?
UGISense’s primary industry is Drug Discovery.
-
Is UGISense a private or public company?
UGISense is a Private company.
-
What is UGISense’s current revenue?
The current revenue for UGISense is .
-
How much funding has UGISense raised over time?
UGISense has raised $1.34M.
-
Who are UGISense’s investors?
Sparkasse Dortmund and Lead Discovery Center have invested in UGISense.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process